Project Grant R43CA301971
Award Date 9/15/25
Completion Date 8/31/26
Dollars Obligated $303K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This $677,176 federal Project Grant award, funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports the development of an interstitial chemophototherapy (I-CPT) approach for treating locally advanced pancreatic cancer. The grantee, The Research Foundation For The State University Of New York (RF SUNY), will advance its long-circulating liposomal irinotecan formulation integrated with porphyrin-phospholipid (IRT-POP) for photoablation of large...
- The federal Project Grant award of $268,345 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel immunotherapy for pancreatic cancer. The primary awardee, Sanford Burnham Prebys Medical Discovery Institute, will investigate the PSGL-1/VISTA axis as a potential target for boosting the anti-tumor immune response in pancreatic tumors. This 2-year project, with a start date of Mar 10, 2025 and end date of Feb 28, 2027, aims to elucidate...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Rochester provides $639,098 to develop an innovative treatment for metastatic pancreatic cancer. The research aims to overcome both intrinsic and extrinsic barriers to treatment efficacy, specifically by targeting the tumor microenvironment through a combination of local radiotherapy and intratumoral immunotherapy using a novel mRNA-based nanoparticle delivery system. The...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to support research by Oncotab, Inc. on optimized targeted radiotherapy for pancreatic cancer. The key objectives are to develop a tumor-specific antibody (HTAB004) and a tandem single-chain variable fragment (scFv) targeting agent labeled with alpha and beta particle-emitting radioisotopes. This research aims to overcome the challenge of the desmoplastic stroma in pancreatic...
- The National Cancer Institute (NCI) awarded a Project Grant, under CFDA 93.394 Cancer Detection and Diagnosis Research, to Case Western Reserve University (CWRU) for $654,681 starting on December 1, 2024. The goal of this 5-year project is to develop innovative anticancer nanovaccines utilizing multifunctional ionizable lipid nanoparticles for the curative treatment of pancreatic ductal adenocarcinoma (PDAC). The research aims to design and evaluate these nanovaccines, assess their therapeutic...
- This $118,722 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to develop a novel immunotherapy for pancreatic cancer. The grant funding will be used by Emory University to engineer CD4+ T cells expressing high levels of the enzyme CD26 and equip them with a chimeric antigen receptor (CAR) targeting mesothelin, a protein expressed on pancreatic tumor cells. The research aims to harness the favorable properties of CD26+ T cells to...
- This Project Grant, awarded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), funds the development and validation of a novel armored CAR-T immunotherapeutic for the treatment of pancreatic ductal adenocarcinoma (PDAC). The $400,835 award to Cambium Oncology LLC aims to engineer CAR-T cells that can secrete a VIP receptor antagonist to disrupt the immunosuppressive tumor microenvironment in PDAC. The 1-year project involves developing and validating...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $162,486 to the University of Miami to support research into a novel immunotherapy approach for pancreatic cancer using microRNA-29a. The goal is to determine how microRNA-29a can regulate T cell exhaustion and restore anti-tumor immunity in pancreatic ductal adenocarcinoma (PDAC), which has a very low 5-year survival rate of 12%. The research will utilize the KPC mouse model of PDAC...
- The National Cancer Institute (NCI) awarded a $654,197 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The General Hospital Corporation (Massachusetts General Hospital) to develop and characterize patient-derived xenograft (PDX) tumor models that represent the major molecular subtypes of pancreatic ductal adenocarcinoma (PDAC). The grant aims to: 1) define the molecular subtypes of PDAC that respond to standard-of-care chemotherapies, 2) elucidate the contribution of...
- The National Cancer Institute awarded a $119,858 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Regents of the University of Minnesota, Office of Sponsored Projects Administration. The award supports research to elucidate mechanisms governing immune surveillance and resistance to antitumor T cell response in pancreatic cancer. The project aims to identify ways to safely promote T cell-mediated destruction of pancreatic cancer through combinatorial immunotherapies....